State of New Jersey Common Pension Fund D Sells 4,371 Shares of Amgen Inc. $AMGN

State of New Jersey Common Pension Fund D trimmed its position in shares of Amgen Inc. (NASDAQ:AMGN) by 2.3% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 183,994 shares of the medical research company’s stock after selling 4,371 shares during the quarter. State of New Jersey Common Pension Fund D’s holdings in Amgen were worth $60,223,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently made changes to their positions in the company. Board of the Pension Protection Fund acquired a new position in Amgen in the 4th quarter valued at approximately $26,000. Olistico Wealth LLC acquired a new position in shares of Amgen during the fourth quarter worth $33,000. Cloud Capital Management LLC bought a new stake in shares of Amgen in the third quarter worth $34,000. Ares Financial Consulting LLC acquired a new stake in Amgen in the fourth quarter valued at $34,000. Finally, Saranac Partners Ltd bought a new position in Amgen during the 3rd quarter worth $37,000. 76.50% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on the company. Morgan Stanley upped their price target on Amgen from $309.00 to $326.00 and gave the company an “equal weight” rating in a research report on Tuesday. Deutsche Bank Aktiengesellschaft lifted their price objective on Amgen from $285.00 to $295.00 and gave the stock a “hold” rating in a research note on Thursday, February 5th. Mizuho increased their target price on shares of Amgen from $280.00 to $295.00 and gave the company an “outperform” rating in a research report on Tuesday, February 10th. Wall Street Zen downgraded shares of Amgen from a “buy” rating to a “hold” rating in a research report on Saturday, April 25th. Finally, Truist Financial upped their price objective on shares of Amgen from $318.00 to $319.00 and gave the company a “hold” rating in a research note on Thursday, January 8th. One analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, fourteen have assigned a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $356.62.

Amgen Price Performance

Shares of AMGN opened at $342.28 on Thursday. Amgen Inc. has a 52-week low of $261.43 and a 52-week high of $391.29. The company has a debt-to-equity ratio of 5.78, a quick ratio of 0.90 and a current ratio of 1.14. The business’s 50 day moving average price is $358.65 and its two-hundred day moving average price is $340.41. The firm has a market cap of $184.72 billion, a PE ratio of 24.11, a price-to-earnings-growth ratio of 3.36 and a beta of 0.47.

Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share for the quarter, beating the consensus estimate of $4.76 by $0.53. The company had revenue of $9.87 billion during the quarter, compared to analyst estimates of $9.46 billion. Amgen had a net margin of 20.98% and a return on equity of 148.37%. Amgen’s revenue for the quarter was up 8.6% compared to the same quarter last year. During the same quarter in the previous year, the business posted $5.31 EPS. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. On average, equities analysts anticipate that Amgen Inc. will post 22.16 EPS for the current year.

Amgen Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 5th. Stockholders of record on Friday, May 15th will be given a dividend of $2.52 per share. This represents a $10.08 dividend on an annualized basis and a dividend yield of 2.9%. The ex-dividend date of this dividend is Friday, May 15th. Amgen’s dividend payout ratio is 70.84%.

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.